| Trastuzumab Emtansine studied in …STUDIED_INderived126 of 126show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 126 trials list this drug (43 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06324357Phase 1/Phase 2 · recruiting Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Esophageal Adenocarcinoma,Gastric Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04266249Phase 2 · active not recruiting CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy · 126 trials list this drug (43 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081609Phase 1/Phase 2 · active not recruiting A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies · 126 trials list this drug (43 active) | — | — | Solid Neoplasm,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 126 trials list this drug (43 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02675829Phase 2 · completed Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers · 126 trials list this drug (43 active) | — | — | Malignant Lung Neoplasm,Malignant Urinary Tract Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 126 trials list this drug (43 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04873362Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00781612Phase 2 · active not recruiting A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06595563Phase 2 · terminated HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893109Phase 2 · recruiting ATEMPT 2.0: Adjuvant T-DM1 vs TH · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05408845Phase 2 · recruiting Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers · 126 trials list this drug (43 active) | — | — | Malignant Major Salivary Gland Neoplasm,Salivary Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975647Phase 3 · active not recruiting A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06316531Phase 3 · active not recruiting A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05673928Phase 2 · recruiting A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) · 126 trials list this drug (43 active) | — | — | Solid Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06126640Phase 3 · active not recruiting A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673029Phase 3 · recruiting A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05323955Phase 2 · active not recruiting Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 126 trials list this drug (43 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04457596Phase 3 · active not recruiting T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial · 126 trials list this drug (43 active) | — | — | Breast Carcinoma,Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578116Phase 3 · not yet recruiting Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis · 126 trials list this drug (43 active) | — | — | Oligometastatic Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587740Phase 2 · active not recruiting ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04622319Phase 3 · active not recruiting A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) · 126 trials list this drug (43 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439110Phase 2 · active not recruiting Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) · 126 trials list this drug (43 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06968585Phase 3 · active not recruiting A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314481Phase 2 · completed Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity · 126 trials list this drug (43 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02326974Phase 2 · active not recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA · 126 trials list this drug (43 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04620187Phase 2 · recruiting Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas · 126 trials list this drug (43 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486352Phase 1/Phase 2 · recruiting A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer · 126 trials list this drug (43 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01853748Phase 2 · completed T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348134Phase 2 · recruiting Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery · 126 trials list this drug (43 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02226276NA · active not recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415215Phase 3 · completed A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07389876recruiting Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma · 126 trials list this drug (43 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01494662Phase 2 · completed HKI-272 for HER2-Positive Breast Cancer and Brain Metastases · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830889Phase 3 · recruiting A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01975142Phase 2 · completed Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03529110Phase 3 · active not recruiting DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06265428Phase 3 · active not recruiting A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04419181Phase 2 · withdrawn Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05945927completed A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07008976Phase 3 · recruiting Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04740918Phase 3 · terminated A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04341181Phase 2 · recruiting ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · 126 trials list this drug (43 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01772472Phase 3 · completed A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042051Phase 1 · terminated Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05650879Phase 1 · active not recruiting ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288777Phase 2/Phase 3 · recruiting Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680442Phase 2 · recruiting Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01565200Phase 2 · completed HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 · 126 trials list this drug (43 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06846437Phase 3 · recruiting JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745965Phase 2 · completed A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03032107Phase 1 · completed A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04675827Phase 2 · terminated De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03726879Phase 3 · completed A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03530696Phase 2 · completed T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer · 126 trials list this drug (43 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06313086Phase 3 · recruiting DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06125834Phase 2 · unknown Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06299852NA · unknown Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03709082Phase 1/Phase 2 · terminated Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01120184Phase 3 · completed A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 126 trials list this drug (43 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 126 trials list this drug (43 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04197687Phase 2 · unknown TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03190967Phase 1/Phase 2 · terminated T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Malignant Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03084939Phase 3 · completed Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04924699Phase 2/Phase 3 · unknown A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05754502unknown Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02236000Phase 1/Phase 2 · completed A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784599Phase 2 · terminated T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC · 126 trials list this drug (43 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03364348Phase 1 · completed 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05560308NA · unknown Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02657343Phase 1/Phase 2 · completed An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429684Phase 3 · unknown Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01966471Phase 3 · completed A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04351230Phase 2 · withdrawn T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01904903Phase 2 · completed Cardiac Safety Study in Patients With HER2 + Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702571Phase 3 · completed A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04398914Phase 2 · active not recruiting Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04296942Phase 1 · terminated BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04298918Phase 1/Phase 2 · terminated A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03894007Phase 2 · terminated Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer · 126 trials list this drug (43 active) | — | — | Early Stage Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02073487Phase 2 · completed Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02658734Phase 4 · completed A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01835236Phase 2 · completed Trastuzumab & Pertuzumab Followed by T-DM1 in MBC · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02924883Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702558Phase 2 · terminated A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03429101Phase 1 · terminated A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01983501Phase 1 · completed A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02038010Phase 1 · completed BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158947Phase 2 · unknown A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone · 126 trials list this drug (43 active) | — | — | Brain Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04301375Phase 2 · not yet recruiting Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) · 126 trials list this drug (43 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02605915Phase 1 · completed Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer · 126 trials list this drug (43 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02318901Phase 1/Phase 2 · terminated Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer · 126 trials list this drug (43 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm,Malignant Esophageal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02999672Phase 2 · completed A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors · 126 trials list this drug (43 active) | — | — | Pancreatic Carcinoma,Cholangiocarcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02289833Phase 2 · completed A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 126 trials list this drug (43 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02131064Phase 3 · completed A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00833963completed A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02658084Phase 1/Phase 2 · terminated Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02073916Phase 1 · completed T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03153163Phase 1 · completed Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer · 126 trials list this drug (43 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03418558Phase 2 · unknown Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. · 126 trials list this drug (43 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02135159Phase 1 · completed Patients With Brain Metastases From HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01816035Phase 1 · completed Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01641939Phase 2/Phase 3 · terminated A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer · 126 trials list this drug (43 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00934856Phase 1/Phase 2 · completed A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00679211Phase 2 · completed A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02144012Phase 3 · terminated A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01120561no longer available A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00928330Phase 1 · completed Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01513083Phase 1 · completed A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00829166Phase 3 · completed A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419197Phase 3 · completed A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02725541Phase 2 · withdrawn Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951665Phase 1/Phase 2 · completed A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00932373Phase 1 · completed A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01196052Phase 2 · completed A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00679341Phase 2 · completed A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00875979Phase 1/Phase 2 · completed A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00943670Phase 2 · completed Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00509769Phase 2 · completed A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer · 126 trials list this drug (43 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |